Prognostic significance of systemic inflammatory parameters in high-grade glial tumor patients: Two center experience
Open Access
- 19 April 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (16) , e37726
Abstract
We aimed to determine the prognostic values of the neutrophil-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, body mass index, and prognostic nutritional index scores in patients with high-grade glioma. This was a retrospective observational case series. Between 2015 and 2020, 79 patients with high-grade gliomas 2 oncology centers were included in our study. All patients (n = 79) had high-grade glial tumors and were treated with RT. Sixty-nine (87.3%) patients died, and the median 2 years overall survival was 12.7 months. Recurrence was observed in 25 (31.6%) patients at the end of the treatment. The median recurrence free survival was 24.4 months. There was no significant correlation between systemic inflammation indicators and survival parameters for OS and RFS. Only a marginally significant association between the neutrophil-lymphocyte ratio and RFS was found. Systemic inflammatory parameters and outcomes were not significantly correlated in patients with high-grade gliomas.Keywords
This publication has 12 references indexed in Scilit:
- The prognostic value of the preoperative inflammatory index on the survival of glioblastoma patientsNeurological Sciences, 2022
- Cancer statistics, 2022CA: A Cancer Journal for Clinicians, 2022
- Influence of neutrophil–lymphocyte ratio in prognosis of glioblastoma multiformeJournal of Neuro-Oncology, 2017
- Preoperative inflammation markers and IDH mutation status predict glioblastoma patient survivalOncotarget, 2017
- Pre-treatment neutrophil-to-lymphocyte ratio is associated with neutrophil and T-cell infiltration and predicts clinical outcome in patients with glioblastomaBMC Cancer, 2015
- The association of pre-treatment neutrophil to lymphocyte ratio with overall survival in patients with glioblastoma multiformeJournal of Neuro-Oncology, 2013
- Molecular pathways in cancer-related inflammationBiochemia Medica, 2011
- Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent gliomaNeuro-Oncology, 2009
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005